A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Latest Information Update: 03 Jun 2024
Price :
$35 *
At a glance
- Drugs Guretolimod (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sumitomo Pharma America; Sumitomo Pharma Oncology
- 03 May 2024 Status changed from completed to discontinued. Due to changing landscape, the sponsor decided to terminate the development of the program.
- 13 Apr 2023 Status changed from recruiting to completed.
- 12 Oct 2022 Planned End Date changed from 1 Sep 2025 to 1 Jan 2023.